Qiangguo Ao

ML models have shown high average discrimination for AKI occurrence and post-AKI mortality, supporting their potential value for AKI risk stratification and early warning, but high levels of heterogeneity, limited external or prospective validation, and inconsistent reporting of model calibration and clinical utility mean that substantial barriers remain before routine clinical deployment.